Skip Navigation


JAC Advance Access originally published online on February 18, 2005
Journal of Antimicrobial Chemotherapy 2005 55(4):574-578; doi:10.1093/jac/dki032
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
55/4/574    most recent
dki032v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Streit, J. M.
Right arrow Articles by Jones, R. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Streit, J. M.
Right arrow Articles by Jones, R. N.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions{at}oupjournals.org

Daptomycin tested against 915 bloodstream isolates of viridans group streptococci (eight species) and Streptococcus bovis

Jennifer M. Streit1, Judith N. Steenbergen2, Grace M. Thorne2, Jeffrey Alder2 and Ronald N. Jones1,3,*

1 The JONES Group/JMI Laboratories, North Liberty, IA; 2 Cubist Pharmaceuticals, Lexington, MA; 3 Tufts University School of Medicine, Boston, MA, USA


* Correspondence address. The JONES Group/JMI Laboratories, Inc., 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA. Tel: +1-319-665-3370; Fax: +1-319-665-3371; Email: ronald-jones{at}jmilabs.com

Objectives: To evaluate the activity of daptomycin tested against numerous species of viridans group streptococci and Streptococcus bovis, which are associated with wound infections, sepsis, cellulitis, endocarditis, abscesses and dental caries. The incidence of penicillin-resistant (non-susceptible) and MLSB-resistant strains among viridans group streptococci often varies by species.

Methods: The activity of daptomycin was compared with seven other antimicrobial classes using reference broth microdilution and disc diffusion methods tested against 915 bacteraemic isolates of streptococci (815 viridans group strains; 100 S. bovis).

Results: Among all species of viridans group streptococci and S. bovis, 99.9% of isolates were susceptible to daptomycin (MIC values, ≤ 0.016–2 mg/L). In contrast, penicillin, erythromycin and tetracycline susceptibility varied widely between species. Erythromycin susceptibility was in the range 48.6–88.7%, penicillin susceptibility in the range 65.5–98.1% and tetracycline in the range 35.0–93.9%. The inter-method agreement between daptomycin and linezolid resistance (comparison agent) disc diffusion and broth microdilution test results was high, each showing near complete susceptibility (99.9%).

Conclusions: Daptomycin is an active antimicrobial agent that has a usable potency against eight species of viridans group streptococci, as well as S. bovis, with all MIC values at ≤2 mg/L.

Keywords: penicillin resistance , S. bovis , Gram-positive bloodstream infections


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Antimicrob. Agents Chemother.Home page
N. A. Ahmed, F. C. Petersen, and A. A. Scheie
AI-2/LuxS Is Involved in Increased Biofilm Formation by Streptococcus intermedius in the Presence of Antibiotics
Antimicrob. Agents Chemother., October 1, 2009; 53(10): 4258 - 4263.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
R. E. Warren
Daptomycin in endocarditis and bacteraemia: a British perspective
J. Antimicrob. Chemother., November 1, 2008; 62(suppl_3): iii25 - iii33.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.